Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) EBIT (2024 - 2025)

Allarity Therapeutics' EBIT history spans 2 years, with the latest figure at -$2.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 119.86% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$12.6 million, down 141.11%, while the annual FY2025 figure was -$12.6 million, 141.11% down from the prior year.
  • EBIT reached -$2.9 million in Q4 2025 per ALLR's latest filing, down from -$2.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $14.7 million in Q4 2024 to a low of -$12.3 million in Q3 2024.